Persons with chronic obstructive pulmonary disease (COPD) often have bouts of coughing and breathlessness resulting from limited airflow. These symptoms place a heavy physical burden on those with the disease.
In COPD clinical trials, researchers study symptoms but often don’t include patient insights. In addition, researchers are necessarily selective about which participants make up these types of trials. That limitation can make translating study findings into real-world clinical practice guidance challenging.
The Salford Lung Study (SLS) in COPD studied different treatments and was designed to be representative of patients in clinical practice. It found that patients treated with fluticasone furoate and vilanterol had fewer episodes of worsening symptoms.
Analysis revealed that COPD symptoms had a significant impact on mobility and in turn on quality of life. Patients cited breathlessness as the symptom that most affected their daily functioning, activities, and self-care.
By evaluating outcomes not traditionally examined in clinical trials, researchers gained insight into patients’ experiences. They learned that beyond the symptoms themselves, people with COPD are more concerned about the effect these conditions have on their activities of daily living.
The findings of this follow-up study have provided significant additional knowledge to the SLS COPD study findings.
Read the full-text article of this study:
Doward L, Svedsater H, Whalley D, Crawford R, Leather D, Lay-Flurrie J, Bosanquet N. Salford Lung Study in chronic obstructive pulmonary disease (SLS COPD): follow-up interviews on patient-centred outcomes. NPJ Prim Care Respir Med. 2017 Dec 15;27(1):66. doi: 10.1038/s41533-017-0066-2.